AMERICA’S ARMY WINNING IN A COMPLEX WORLD

treatment of injuries and return to duty or civilian life. Ongoing efforts
address multiple threats to our Soldiers’ health and readiness. The
Medical S&T Portfolio’s mission is to develop capabilities that ensure
forces sustain optimal health, are protected from disease and injury, and
receive optimal care in the event of injury or illness.
The Medical S&T Portfolio investment strategy covers subportfolios
that include clinical and rehabilitative medicine, combat casualty
care, military infectious disease, military operational medicine and
systems biology. The Medical S&T Portfolio is focused on materiel and
knowledge-based medical solutions including the delivery of improved
combat casualty care, enhanced survivability, reduced impact due to
injury and optimized downrange medical footprint. The portfolio also
is seeking ways to enhance recovery, rehabilitation and reintegration of
our Wounded Warriors in terms of duty, performance and quality of life.
The portfolio is also developing capability options to improve diagnosis,
prevention and treatment of diseases with major impact on mission
effectiveness and will enhance physiological performance in a variety
of mission settings through solutions focused on maintaining, restoring
and improving warfighter health and readiness, injury prevention and
reduction, environmental health and protection, and psychological
health and resilience. The Medical S&T Portfolio is preserving combat
effectiveness and survivability through medical countermeasures to
chemical and biological threats and clinical diagnostic capabilities.
Industry partners are an integral part of medical capability development
and fielding. Army medical S&T labs collaborate with university
and industrial partners to develop diagnostic tools and medical
countermeasures (vaccines, therapeutics), in addition to capitalizing on
the industrial base for use of diagnostic equipment supporting both the
continental U.S. and deployed medical functions.
For example, Psychological
Health and Resilience and
Traumatic Brain Injury (TBI)
research efforts support laboratory
validation studies and field
demonstrations of biomedical
products designed to counteract
myriad environmental and
physiological stressors and materiel
hazards Soldiers encounter in training and operational environments.
The resulting biomedical capabilities are focused on protecting,
sustaining and enhancing Soldiers’ cognitive, physiological, physical
and social performance. Key efforts are providing capability solutions in
the form of technologies and tools that enhance warfighter survivability,
assessment and prediction of injuries, assessments for postconcussive
syndrome, and enhancing performance during continuous operations.
Physiological health and environmental protection, injury prevention
and reduction and psychological health and resilience are the three main
thrust areas.
The Army’s Infectious Diseases
(Drugs and Vaccines) efforts will
mature and demonstrate medical
countermeasures, such as drugs
and vaccines, and diagnostic
tools for wound infections and
militarily important naturally
occurring infectious diseases
yielding capabilities approved by
the Food and Drug Administration. Research priorities are identified
by worldwide medical surveillance and military threat analysis. These
S&T efforts also support testing of personal protective measures such
as repellents and insecticides regulated by the Environmental Protection
Agency. The portfolio also develops and evaluates vaccine candidates to
prevent diseases that impact warfighter readiness, such as the three major
WEAPON SYSTEMS HANDBOOK 2016 349